Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Technologies (NASDAQ: LQDA) announced the rescheduling of its special stockholder meeting to November 13, 2020. Initially set for October 21, the meeting will now be held virtually. The company recently received an unsolicited offer related to its LIQ861 product but determined it did not constitute a superior proposal, thus terminating discussions. The Board of Directors is urging stockholders to vote 'FOR' the proposals at the upcoming meeting, reaffirming their commitment to the planned merger with RareGen, LLC.
Liquidia Technologies (Nasdaq:LQDA) will report its third quarter 2020 financial results on November 6, 2020. A webcast and conference call to discuss these results is scheduled for November 9, 2020, at 8:00 a.m. ET. The company specializes in developing novel biopharmaceuticals using its proprietary PRINT® technology, focusing on two main product candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain. The event will allow investors to gain insights into the company's performance and future outlook.
Liquidia Technologies (Nasdaq:LQDA) announced it will report its third quarter 2020 financial results on November 6, 2020. A conference call and webcast will follow on November 9, 2020, at 8:00 a.m. ET to discuss these results and provide a corporate update. The company focuses on developing novel products using its proprietary PRINT® technology, particularly LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management. This strategy underlines their commitment to improving patient outcomes through advanced therapies.
Liquidia Technologies has postponed its special stockholder meeting originally set for October 21, 2020, to evaluate an unsolicited offer for its LIQ861 product candidate. This offer is contingent upon terminating a previously arranged merger agreement. The company's board is assessing whether this offer qualifies as a 'Superior Proposal' as defined in the merger terms. Further information regarding the special meeting will be provided after the review concludes.
Liquidia Technologies (NASDAQ: LQDA) announced that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review of its patent claims against United Therapeutics' U.S. Patent No. 9,604,901 (‘901) regarding Tyvaso®. The PTAB declined the review for U.S. Patent No. 9,593,066 (‘066). CEO Neal Fowler emphasized the importance of this review for advancing LIQ861, a treatment for pulmonary arterial hypertension (PAH). LIQ861's New Drug Application is currently under review by the FDA, while a 30-month stay on approval relates to ongoing litigation with United Therapeutics.
Liquidia Technologies has appointed Dr. Gerald M. O’Brien as Vice President of Pulmonary Clinical Development, effective immediately. With 25 years of experience in pulmonary critical care, Dr. O’Brien aims to enhance Liquidia's efforts in treating pulmonary arterial hypertension (PAH). Previously, he led the PRIMEx trial at Complexa Inc. Liquidia focuses on developing innovative products using its proprietary PRINT® technology, specifically for PAH and post-operative pain management.
Liquidia Technologies (NASDAQ: LQDA) has announced a special meeting for stockholders on October 21, 2020, to vote on the acquisition of RareGen, LLC, following the SEC's approval of the registration statement relating to the merger. Stockholders as of September 14, 2020, are eligible to vote. CEO Neal Fowler emphasized the strategic importance of the acquisition, which aims to benefit shareholders and enhance treatment options for pulmonary arterial hypertension patients. The transaction remains subject to customary closing conditions and stockholder approval.
Liquidia Technologies (NASDAQ: LQDA) announced receiving a Notice of Allowance from the USPTO for a patent application related to LIQ861, a dry powder treprostinil under FDA review for pulmonary arterial hypertension. This patent is expected to enhance Liquidia's intellectual property position and is a vital step towards commercialization. The patent is anticipated to be issued in Q4 2020, with a term extending until 2037. This development signals Liquidia's commitment to addressing unmet needs in PAH treatment.
Liquidia Technologies (NASDAQ: LQDA) has appointed Steven Bariahtaris as interim Chief Financial Officer following the resignation of Richard Katz. Bariahtaris brings nearly 24 years of experience from Johnson & Johnson, where he held several executive roles. His appointment comes as Liquidia prepares for the acquisition of RareGen and the potential launch of LIQ861, aimed at treating pulmonary arterial hypertension. CEO Neal Fowler emphasized Bariahtaris's strategic insights and financial expertise as crucial for the company's growth during this transformative period.
Liquidia Technologies (LQDA) has received FDA acceptance for its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH), with a Prescription Drug User Fee Act (PDUFA) goal date set for November 24, 2020. The company reported no revenues for Q2 2020, a decrease from $8.1 million in Q2 2019, resulting in a net loss of $13.9 million. R&D expenses decreased while G&A expenses rose significantly due to legal costs associated with the RareGen acquisition. Liquidia raised $75 million from a public offering and appointed Tushar Shah, M.D. as Chief Medical Officer.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
